P2 Receptor

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1258 Prasugrel <1 mg/mL 30 mg/mL 7 mg/mL
S1415 Clopidogrel 78 mg/mL 83 mg/mL 46 mg/mL
S2855 MRS 2578 <1 mg/mL 42 mg/mL <1 mg/mL
S4079 Ticagrelor <1 mg/mL 100 mg/mL 53 mg/mL
S1984 Ticlopidine HCl 4 mg/mL 1 mg/mL 1 mg/mL
S8725 A-804598 <1 mg/mL 63 mg/mL 6 mg/mL
S3737 Cangrelor Tetrasodium 100 mg/mL 2 mg/mL <1 mg/mL
S8519 A-317491 <1 mg/mL 100 mg/mL 100 mg/mL
S7705 A-438079 HCl 61 mg/mL 61 mg/mL 20 mg/mL
S4637 Prasugrel Hydrochloride <1 mg/mL 46 mg/mL 9 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations


Prasugrel is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.



Clopidogrel is an oral, thienopyridine class antiplatelet agent.


MRS 2578

MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.



Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist with Ki of 2 nM.


Ticlopidine HCl

Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM.



A-804598 is a selective P2X7R antagonist with high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.


Cangrelor Tetrasodium

Cangrelor is a potent, competitive P2Y12 receptor inhibitor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation.



A-317491 is a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors with Ki values of 22 nM and 9 nM for human P2X3 and P2X2/3 receptors.


A-438079 HCl

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.


Prasugrel Hydrochloride

Prasugrel hydrochloride is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.